loading
Schlusskurs vom Vortag:
$2.95
Offen:
$2.86
24-Stunden-Volumen:
30,897
Relative Volume:
2.60
Marktkapitalisierung:
$41.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.26M
KGV:
-1.2295
EPS:
-2.261
Netto-Cashflow:
$-13.50M
1W Leistung:
-12.78%
1M Leistung:
-16.84%
6M Leistung:
-42.78%
1J Leistung:
+26.78%
1-Tages-Spanne:
Value
$2.755
$2.95
1-Wochen-Bereich:
Value
$2.755
$3.2999
52-Wochen-Spanne:
Value
$2.1446
$11.44

Intensity Therapeutics Inc Stock (INTS) Company Profile

Name
Firmenname
Intensity Therapeutics Inc
Name
Telefon
203-221-7381
Name
Adresse
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Name
Mitarbeiter
17
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
INTS's Discussions on Twitter

Vergleichen Sie INTS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
INTS 2.78 41.32M 0 -16.26M -13.50M -2.261
VRTX 447.30 115.43B 10.63B -479.80M -1.35B 13.33
REGN 745.59 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 592.15 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.57 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 104.51 24.49B 3.30B -501.07M 1.03B 11.54

Intensity Therapeutics Inc Aktie (INTS) Neueste Nachrichten

pulisher
10:47 AM

Shelton-based Intensity Therapeutics gains $3M investment - Hartford Business Journal

10:47 AM
pulisher
08:18 AM

Intensity Therapeutics secures $3 million in stock offering - Investing.com

08:18 AM
pulisher
08:00 AM

Intensity Therapeutics Raises $3M Through Stock Offering & Warrant Placement | INTS Stock News - StockTitan

08:00 AM
pulisher
Nov 18, 2024

Intensity reports promising sarcoma treatment results - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at - StreetInsider.com

Nov 18, 2024
pulisher
Nov 18, 2024

Intensity Therapeutics' Cancer Drug Triples Survival Time in Phase 1/2 Sarcoma Trial | INTS Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 14, 2024

Q&A: New cancer medication to treat refractory solid tumours - Digital Journal

Nov 14, 2024
pulisher
Nov 13, 2024

Intensity Therapeutics Reports Wider Q3 Loss, Advances Key Cancer Drug Trials | INTS Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

3 US Penny Stocks With Market Caps Under $200M To Watch - Simply Wall St

Nov 13, 2024
pulisher
Nov 08, 2024

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting - The Malaysian Reserve

Nov 08, 2024
pulisher
Nov 06, 2024

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22) - Quantisnow

Nov 06, 2024
pulisher
Nov 05, 2024

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition - The Manila Times

Nov 05, 2024
pulisher
Nov 05, 2024

TScan Therapeutics Announces Upcoming Oral Presentation of - GlobeNewswire

Nov 05, 2024
pulisher
Nov 01, 2024

INTSIntensity Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 01, 2024
pulisher
Oct 31, 2024

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Oct 31, 2024
pulisher
Oct 30, 2024

Balancing Decisions Around Breast Cancer Treatment and Fertility, Breastfeeding - Curetoday.com

Oct 30, 2024
pulisher
Oct 29, 2024

New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy - Yahoo Finance

Oct 29, 2024
pulisher
Oct 24, 2024

Intensity Therapeutics grants stock options to top executives By Investing.com - Investing.com South Africa

Oct 24, 2024
pulisher
Oct 23, 2024

Intensity Therapeutics grants stock options to top executives - Investing.com

Oct 23, 2024
pulisher
Oct 18, 2024

High-intensity, low-impact training (HILIT) is gentle on joints and can boost your metabolism. Here’s how to get started - Yahoo Finance

Oct 18, 2024
pulisher
Oct 16, 2024

Biliary Tumor Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart

Oct 16, 2024
pulisher
Oct 16, 2024

SONIRE’s HIFU Therapy System Designated as Breakthrough Device by FDA - BioSpace

Oct 16, 2024
pulisher
Oct 16, 2024

SONIRE's HIFU Therapy System Designated as Breakthrough Device by FDA - The Manila Times

Oct 16, 2024
pulisher
Oct 15, 2024

Cholangiocarcinoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Oct 15, 2024
pulisher
Oct 15, 2024

Thoracic Re-irradiation With Definitive External Beam Radiation Therapy Using Intensity Modulated Radiation Therapy: A Case Report - Cureus

Oct 15, 2024
pulisher
Oct 02, 2024

Herceptin, Perjeta Regimen May Be Effective Without Chemo in Breast Cancer - Curetoday.com

Oct 02, 2024
pulisher
Sep 29, 2024

Side Effects, Quality of Life Important to Consider in Breast Cancer Subset - Curetoday.com

Sep 29, 2024
pulisher
Sep 27, 2024

There is Nothing Pink About Breast Cancer - Curetoday.com

Sep 27, 2024
pulisher
Sep 26, 2024

Head and Neck Cancer Therapeutics Market Overview: Breakthrough Treatments, Technological Innovations, and ... - WhaTech

Sep 26, 2024
pulisher
Sep 24, 2024

An Analysis of Ideaya Biosciences Inc (IDYA)’s Potential Price Growth - Knox Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Weekly Investment Analysts’ Ratings Changes for Incyte (INCY) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Inogen: Upside Seems Limited After Big Move Up (NASDAQ:INGN) - Seeking Alpha

Sep 24, 2024
pulisher
Sep 24, 2024

InvenTrust Properties (NYSE:IVT) Sees Strong Trading Volume - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Skandinaviska Enskilda Banken AB publ Increases Position in Itron, Inc. (NASDAQ:ITRI) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Ideaya Biosciences price target lowered to $52 from $54 at Wedbush - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

Hoosier Hysterics Podcast: Sisley commits, plus IUWBBs Shay Ciezki and Karoline Striplin - 247Sports

Sep 24, 2024
pulisher
Sep 24, 2024

Ideaya Biosciences should be bought on weakness, says Citi - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

Intapp, Inc. (NASDAQ:INTA) Shares Sold by Hood River Capital Management LLC - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

(TIL) Long Term Investment Analysis - Stock Traders Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Low-intensity pulsed ultrasound modulates disease progression in the SOD1 - ScienceDirect.com

Sep 24, 2024
pulisher
Sep 24, 2024

Itim Group PLC Announces Strong Mid-Year Financials - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

ITT Educational Services (OTCMKTS:ESINQ) Stock Price Passes Above Two Hundred Day Moving Average of $0.00 - Defense World

Sep 24, 2024
pulisher
Sep 23, 2024

InvenTrust Properties Corp. Announces Upsizing and Pricing of Common Stock Offering - StockTitan

Sep 23, 2024
pulisher
Sep 23, 2024

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Intense Technologies Limited's (NSE:INTENTECH) CEO For Now - Simply Wall St

Sep 23, 2024
pulisher
Sep 23, 2024

US FDA Closes Out Problem Applications One Federal Register Notice At A Time - Pink Sheet

Sep 23, 2024
pulisher
Sep 23, 2024

Ideaya Biosciences price target lowered to $66 from $68 at Stifel - TipRanks

Sep 23, 2024
pulisher
Sep 23, 2024

BTIG maintains $62 target on Ideaya Biosciences stock - Investing.com

Sep 23, 2024
pulisher
Sep 23, 2024

From Statins to PSCK9 Inhibitors: Choosing the Right Therapy for Cholesterol - Pharmacy Times

Sep 23, 2024
pulisher
Sep 23, 2024

Intercontinental Exchange, Inc. (NYSE:ICE) Shares Sold by Interval Partners LP - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

ILLIT Comeback 'I'll Like You' Mini-Album: Release Date, Tracklist - J-14

Sep 23, 2024
pulisher
Sep 23, 2024

Integra Lifesciences Holdings Corp (IART) Becoming More Attractive for Investors - Knox Daily

Sep 23, 2024

Finanzdaten der Intensity Therapeutics Inc-Aktie (INTS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):